The sbk002 Study Abstract from SBK Has Been Accepted for Presentation at the 2026 American College of Cardiology (ACC) Scientific Sessions

On December 16, 2025, the American College of Cardiology officially accepted the abstract detailing clinical research results of sbk002 (Becondogrel), a next-generation antiplatelet therapy independently developed by Chengdu Shibeikang Biomedical Technology Co., Ltd. (SBK). The study, entitled “PK/PD Characteristics of Becondogrel in Healthy Subjects with Different CYP2C19 Metabolic Genotypes,” will be showcased at ACC Scientific Sessions 2026, one of the world’s most influential cardiovascular conferences.

ACC Scientific Sessions: The Global Gold Standard for Cardiovascular Research and Clinical Excellence

The American College of Cardiology (ACC) Scientific Sessions are widely regarded as the premier global conference in cardiovascular medicine, shaping clinical practice, research priorities, and industry standards worldwide. Each year, the meeting brings together leading cardiologists, researchers, and industry leaders from more than 130 countries. Research presented at ACC frequently informs updates to international guidelines for the diagnosis and treatment of cardiovascular disease.

Acceptance criteria for posters at the ACC Scientific Sessions are comparable to those for featured presentations, emphasizing three core principles: rigorous study design, complete and traceable data, and clinically meaningful conclusions. The selection of the sbk002 study poster reflects its focus on addressing unmet clinical needs and the strong translational relevance of its findings.

sbk002: A Next-Generation Antiplatelet Therapy Designed to Balance Bleeding and Ischemic Risk

Variability in antiplatelet efficacy driven by CYP2C19 genetic polymorphisms is a well-recognized clinical challenge. The efficacy of conventional antiplatelet therapies differs substantially across four metabolic phenotypes: ultra-rapid (UM), extensive (EM), intermediate (IM), and poor metabolizers (PM). Poor metabolizers may experience inadequate drug activation and an increased risk of thrombotic events, while ultra-rapid metabolizers face a higher risk of bleeding due to excessive drug exposure. Although genotype-guided therapy can help inform treatment selection, clinicians continue to face challenges in balancing precision with practicality in routine care.

sbk002 represents a meaningful innovation that directly addresses this long-standing challenge, with the potential to overcome treatment variability driven by genetic polymorphisms. This study is the first to systematically characterize the pharmacokinetic profile of sbk002 across populations with different metabolic genotypes, generating critical data to support the development of personalized dosing strategies.

sbk002 has previously received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration. Its presentation at the ACC Scientific Sessions marks an important step toward global clinical development, with the potential to deliver safer, more convenient antiplatelet therapy options for cardiovascular patients worldwide.